Diaceutics PLC’s Post

Improving patient outcomes with the right test and the right therapy!

Sat on the plane, reflecting on the past three days at the ASCO conference and it has been nothing short of energizing, filled with back-to-back meetings and invaluable interactions. Here are some of my highlights: ✔️Receiving invaluable feedback from our early access users about the product market fit of ImageneOI, our Biomarker Profiling Platform ✔️All the discussions with our strategic and commercial partners who are instrumental in helping us achieve our goals with data access, clinical trial, and clinical pipeline deployments. ✔️Welcoming new customers of our first-in-class LungOI LDT, enabling rapid turnaround of patient diagnostic results to get them on the right drug faster. ✔️Connecting with pharma companies eager to leverage our solutions to enhance biomarker strategies, speed up patient enrollment, and ensure pull-through for their on-market drugs. ✔️It was also fantastic to finally meet in person and spend quality time with some of my new team at Imagene AI (Daniel, Addie and Dean), as well as catching up with the usual suspects and good friends at all the receptions. By the end of it all I, like many who attended, am thoroughly exhausted but not at all complaining. What remains at the forefront of my mind is how exhausted our patients are from their cancer journeys and as an experienced survivor, knowing first-hand the pitfalls in our systems that desperately need fixing, it truly motivates me to keep striving for better solutions. Until next year, Chi-Town! #ASCO2024 #ImmediateOncologyIntelligence #FoundationOI #ImageneOI #LungOI

EY-Parthenon & Innoplexus - a Partex Company's Second Edition of the Autoimmune Innovation Index is Out Now! The report captures the evolving clinical landscape across autoimmune diseases, featuring key global pharma and biotech players working on novel therapeutic modalities to advance these diseases. "In this second edition of the Innovation Index, we, along with experts from EY, have evaluated the changing therapeutic landscape for 18 key autoimmune indications. The focus is on new disease-modifying treatments, novel mechanisms of action, innovative combinatorial or targeted approaches, and recent special approvals by the FDA. We predict the clinical success of late-stage trials launched between April 2022 and June 2023 to identify promising companies, assets, and interventions that will lead the way for better patient care in the future." Dr. Gunjan Bhardwaj, Founder & CEO, Partex NV Check out our second edition published: https://lnkd.in/dwMgmf_w Authors: Dr. Gunjan Bhardwaj Dr. Ying Strebe Klaus Ort Dr. Sanika Bhide Ph.D #innovation #biopharma #pharmanews #healthcare #EY #research #autoimmunedisease #partex Nitish Jain, CFA, Dr. Tapashi Mandal, Ph.D. Aastha Ahuja

🚀 Elevate Your Clinical Trial with Imaging Endpoints’ Customized Proposal 🚀 At Imaging Endpoints we pride ourselves on delivering proposals that are truly customized to meet the unique needs of each sponsor’s trial, providing a road map to success. Our approach ensures transparency, thoroughness, and a proven track record, highlighted by a remarkable 95% market authorization rate for registration trials we support. Why Choose Us? • Tailored Solutions: Each proposal is meticulously crafted to address specific trial requirements, leveraging our deep expertise in clinical trial imaging to provide a road map to success. • Transparent Pricing: Our proposals feature clear, comprehensive pricing with no hidden costs, ensuring complete financial transparency. • Proven Success: With a flawless inspection record and over 150 successful marketing authorizations, our track record speaks for itself. • Collaborative Approach: Our medical, scientific, operations and regulatory experts strive to meet with your team to understand and explain imaging-specific protocol nuances, customizing our approach to better address your trials’ needs. Experience the Imaging Endpoints difference – where expertise meets excellence. Contact us today to learn how our customized proposals can support your clinical trials. Discover More at https://hubs.li/Q02Q5NBT0 📧 Reach out at experts@imagingendpoints.com to schedule a conversation with our business development team. #ClinicalTrials #Oncology #ImagingEndpoints #BusinessDevelopment #Innovation #Biopharma

🚀 Elevate Your Clinical Trial with Imaging Endpoints’ Customized Proposal 🚀 At Imaging Endpoints we pride ourselves on delivering proposals that are truly customized to meet the unique needs of each sponsor’s trial, providing a road map to success. Our approach ensures transparency, thoroughness, and a proven track record, highlighted by a remarkable 95% market authorization rate for registration trials we support. Why Choose Us? • Tailored Solutions: Each proposal is meticulously crafted to address specific trial requirements, leveraging our deep expertise in clinical trial imaging to provide a road map to success. • Transparent Pricing: Our proposals feature clear, comprehensive pricing with no hidden costs, ensuring complete financial transparency. • Proven Success: With a flawless inspection record and over 150 successful marketing authorizations, our track record speaks for itself. • Collaborative Approach: Our medical, scientific, operations and regulatory experts strive to meet with your team to understand and explain imaging-specific protocol nuances, customizing our approach to better address your trials’ needs. Experience the Imaging Endpoints difference – where expertise meets excellence. Contact us today to learn how our customized proposals can support your clinical trials. Discover More at https://hubs.li/Q02BktDl0 📧 Reach out at experts@imagingendpoints.com to schedule a conversation with our business development team. #ClinicalTrials #Oncology #ImagingEndpoints #BusinessDevelopment #Innovation #Biopharma

Join Profound Research at the Society for Clinical Research Sites (SCRS) Global Site Solutions Summit! We're excited to announce that our leadership team will be featured in two insightful discussions during this year's conference in Hollywood, FL. Don't miss the opportunity to hear from our experts: Lora Parahovnik, PhD, MBA - CEO, Profound Research - Session: Therapeutics Roundtable: Diagnostics, Devices, and Biomarkers - Date: Friday, September 27th - Time: 1:00 – 2:35pm A creatively guided session where like minds collaborate to discuss solutions in diagnostics, devices, and biomarkers. Marty Forrest Anderson - COO, Profound Research - Session: Breakout Session III: Regulatory - Date: Saturday, September 28th - Time: 2:15 – 3:15pm Gain key insights into evolving regulations, including updates to GCP ICH-E6, and learn how to prepare your clinical site for future changes. Interested in connecting? Message Profound Research to schedule time with Lora or Marty during the summit. We look forward to collaborating with you! #SCRS2024 #ClinicalResearch #SiteSolutionsSummit #ProfoundResearch #Diagnostics #GCP #RegulatoryCompliance #makeaprofoundimpact

A few weeks ago at the Digital Therapeutics Alliance Summit in Washington, DC, one of the panels discussed the significance of comprehensive and tailored education in the digital therapeutics sector for all stakeholders. Some of my key takeaways were: 1. While education is imperative across all stakeholders for digital therapeutics, the educational space is in its infancy when compared with pharma, biotech and medtech peers 2. Personalization of digital therapeutics solutions to fit individual patient needs and goals is key to uptake and positive outcomes 3. Accessible, convenient feedback channels for patients and caregivers are of utmost importance 4. Active involvement of payers in educational initiatives can address reimbursement and adoption challenges Get in touch if you are interested in learning how Caudex | An IPG Health Company can help you on your DTx educational journey to drive deeper engagement with HCPs and patients. Digital Therapeutics Alliance Digital Health & Care Alliance #HealthInnovation #MedicalEducation

🌟 Soft Cell Labs and Pharmacogenomics! 🌟 Soft Cell Laboratories has validated our new Pharmacogenomics (PGx) genotyping assay. This innovative tool is transforming the landscape of personalized medicine by enabling clinicians to offer targeted therapeutics tailored to each individual patient. Not only does this assay enhance treatment efficacy, but it also promotes cost-effectiveness and efficiency in clinical practice. This breakthrough represents a significant step forward in providing precision medicine solutions that align with the unique needs of every patient. Explore how our PGx genotyping assay can optimize patient care and improve outcomes in your practice. #SoftCellLaboratories #Pharmacogenomics #PersonalizedMedicine #Healthcare #Innovation #ClinicalExcellence Check out this article: https://lnkd.in/gv-e9CRw

Why you should choose Medialis Ltd for all your real-world evidence needs. In today's dynamic world of healthcare, can you be certain your organisation is producing comprehensive and accurate evidence? At Medialis Ltd, we are specialists in delivering robust real-world evidence that supports informed decision-making and drives better outcomes by helping more patients access new treatments sooner. Medialis Ltd can assist you in developing Quality of Life instruments, Disease severity scores, Core datasets, and Cost lists by: • Applying Neutral Theory: Ensuring our methodologies are unbiased and scientifically rigorous. • Using the Jandhyala Method: Utilising advanced techniques to achieve consensus in observations. • Unifying disease observations across geographies and disciplines: Standardising approaches in the practice of observing patients on or off treatment, irrespective of point of view. • Identifying the right patients: Facilitating accurate screening of at-risk populations for timely diagnosis and treatment. • Predicting long-term outcomes: Anticipating future trends in disease progression. • Accurate costing services: Providing detailed cost lists that go beyond basic costs to enhance economic evaluations. For more information and to discuss how our methods can benefit your organisation, contact us at info@medialis.co.uk. #RWE #RealWorldEvidence #CoreDatasets #DiseaseSeverityScore #PatientOutcomes #JandhyalaMethod #NeutralTheory #Neutrality #MedicalAffairs AEterna Zentaris Inc., Alexion Pharmaceuticals, Inc., Antengene, Apollomics, Arena Pharmaceuticals, Inc., argenx, Astellas Pharma, Avadel Inc., Avadel Pharmaceuticals PLC, Boehringer Ingelheim, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CorestemChemon Inc., CSL Behring B.V., Cumberland Pharmaceuticals , CymaBay Therapeutics, EMD Serono, Inc., Italfarmaco, Kite Pharma, ML Bio Solutions, Moderna, MultiVir, Inc., OPKO Health, Inc., Ra Pharmaceuticals, Revolo Biotherapeutics , 德琪医药Antengene, SK Life Science, Inc., Strata Oncology, Syros Pharmaceuticals, Arterys (Acquired by Tempus Labs)

Spherix's Patient Chart Dynamix™ reveals AstraZeneca’s Saphnelo as having the highest use among CLE patients, surpassing its use in SLE or SLE/LN. Approved for SLE and in Phase 3 for CLE, Saphnelo is on track to potentially become the first therapy approved specifically for CLE. 🌟Other promising CLE treatments in the pipeline include Biogen’s litifilimab, Bristol Myers Squibb’ Sotyktu, Amgen’s daxdilimab, Merck’s enpatoran, and Gilead Sciences’s GS-5718. 𝗪𝗵𝗮𝘁 𝘄𝗼𝘂𝗹𝗱 𝘆𝗼𝘂 𝗱𝗼 𝘄𝗶𝘁𝗵 𝘂𝗻𝗽𝗮𝗿𝗮𝗹𝗹𝗲𝗹𝗲𝗱 𝗺𝗮𝗿𝗸𝗲𝘁 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲 𝗮𝗻𝗱 𝟰𝟬𝟬 𝗖𝗟𝗘 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗵𝗮𝗿𝘁𝘀 𝗮𝘁 𝘆𝗼𝘂𝗿 𝗱𝗶𝘀𝗽𝗼𝘀𝗮𝗹❓ #marketresearch #rheumatology #CLE #SLE